HealthDay News — In middle-aged and older adults, anticholinergic drug burden is associated with an increased risk for ...

Pediatric patients with moderate to severe hidradenitits suppurativa may now receive secukinumab following new FDA approval for those aged 12 and up.

Adults aged 18 to 49 years at increased risk for RSV-associated lower respiratory tract disease are now eligible for the ...

A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.

Enh3ance trial results indicate DTX301 reduces ammonia levels by 18% and supports dietary liberalization in patients with OTC deficiency.

Significantly lower risk for clinically relevant bleeding seen with apixaban than rivaroxaban during three-month trial period.

Supplementation does not change four-week cumulative incidence of health care utilization among adults with newly diagnosed COVID-19.

Twenty point six percent of patients followed a switcher trajectory within 12 months, with higher persistence seen for switchers.

Sotyktu’s approval expanded to encompass active psoriatic arthritis; the FDA approves leucovorin for rare disorder, not autism; safety concerns prompt Tazverik withdrawal; FDA to review potential new ...

EyeRising and Sky-n1201 reached ANSI group 1 limits within exposure times of 2.8 and 1.4 seconds for a 7-mm pupil.

From 2023, there was a decrease in use of metabolic and bariatric surgery, with stronger decline for sleeve gastrectomy.

New data show bimekizumab is the first approved biologic to achieve superior outcomes in psoriatic arthritis vs an IL-23 ...